Abstract
Diabetes mellitus is a metabolic disorder leading to hyperglycemia and organ damage. In 2017, the International Diabetes Federation (IDF) reported that about 425 million people living with diabetes, most of which suffer from type 2 diabetes mellitus. The drug development for controlling glucose level is crucial to treat people with type 2 diabetes mellitus. Alpha-amylase plays an imperative role in carbohydrate hydrolysis. Hence, the inhibition of alpha-amylase, which halt the glucose absorption, can be a promising pathway for developing type 2 diabetes mellitus drugs. Natural product has been known as the lead drugs for various diseases. In this research, the fragment merging drug design was performed by employing both the existing drug, voglibose, as the template and the natural product compounds to generate newly constructed ligands. The fragments were acquired from ZINC15 natural product database and then were screened according to Astex’s Rules of Three, pharmacophore properties, and molecular docking simulation. The 482 selected fragments were evaluated under Lipinski’s Rule of Five and toxicity effects using DataWarrior software. The ligands underwent molecular flexible docking simulation followed by the ADME-Tox prediction by using Toxtree, AdmetSAR, and SwissADME software. In the end, two lead compounds showed the best properties as an alpha-amylase inhibitor based on their low ΔGbinding, acceptable RMSD score, favorable pharmacological properties, and molecular interaction.
Keywords
- Type 2 diabetes mellitus
- Alpha-amylase
- Fragment-based drug design
This is a preview of subscription content, access via your institution.
Buying options
References
Hyun, T.K., Eom, S.H., Kim, J.: Molecular docking studies for discovery of plant-derived α-glucosidase inhibitors. Plant Omi. J. 7, 166–170 (2014)
Pontes, J.P.J., Mendes, F.F., Vasconcelos, M.M., Batista, N.R.: Evaluation and perioperative management of patients with diabetes mellitus. A challenge for the anesthesiologist. Rev. Bras. Anestesiol. 68, 75–86 (2018)
Zheng, Y., Ley, S.H., Hu, F.B.: Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature 14, 88–98 (2018)
International Diabetes Federation: IDF Diabetes Atlas Eighth edition. Dipresentasikan pada (2017)
Kaku, K.: Pathophysiology of type 2 diabetes and its treatment policy. Jpn. Med. Assoc. J. 53, 41–46 (2010)
Sharifuddin, Y., Chin, Y.-X., Lim, P.-E., Phang, S.-M.: Potential bioactive compounds from seaweed for diabetes management. Mar. Drugs 13, 5447–5491 (2015)
Shankaraiah, P., Reddy, Y.N.: Alpha amylase expression in Indian type - 2 diabetic plants. J. Med. Sci. 11, 280–284 (2011)
Lahlou, M.: The success of natural products in drug discovery. Pharmacol. Pharm. 4, 17–31 (2013)
Kumar, A., Voet, A., Zhang, K.Y.J.: Fragment based drug design: from experimental to computational approaches. Curr. Med. Chem. 19, 1–19 (2012)
Setlur, A.S., Naik, S.Y., Skariyachan, S.: Herbal lead as ideal bioactive compounds against probable drug targets of Ebola virus in comparison with known chemical analogue: a computational drug discovery perspective. Interdiscip. Sci. Comput. Life Sci. 9, 254–277 (2017)
Scoffin, R., Slater, M.: Virtual elaboration of fragment ideas: growing, merging and linking fragments with realistic chemistry. Drug Discov. Dev. Deliv. 7, 36–40 (2015)
Erlanson, D.A., Mcdowell, R.S., Brien, T.O.: Fragment-based drug discovery. J. Med. Chem. 47, 3463–3482 (2004)
Brayer, G.D., Luo, Y., Withers, S.G.: The structure of human pancreatic a-amylase at 1.8 A resolution and comparisons with related enzymes. Protein Sci. 4, 1730–1742 (1995)
Bhasin, M., Raghava, G.P.S.: Computational methods in genome research. Appl. Mycol. Biotechnol. 6, 179–207 (2006)
Rydzewski, J., Jakubowski, R., Nowak, W.: Communication: entropic measure to prevent energy over-minimization in molecular dynamics simulations. J. Chem. Phys. 143 (2015)
Congreve, M., Carr, R., Murray, C., Jhoti, H.: Fragment-based lead discovery. Drug Discov. Today 8, 876–877 (2003)
Da, C., Kireev, D.: Structural protein − ligand interaction fingerprints (SPLIF) for structure-based virtual screening: method and benchmark study. J. Chem. Inf. Model. 54, 2555–2561 (2014)
Hu, B., Lill, M.A.: Exploring the potential of protein-based pharmacophore models in ligand pose prediction and rangking. J. Chem. Inf. Model. 53, 1179–1190 (2014)
Zuccotto, F.: Pharmacophore features distributions in different classes of compounds. J. Chem. Inf. Comput. Sci. 43, 1542–1552 (2003)
Qing, X., et al.: Pharmacophore modeling: advances, limitations, and current utility in drug discovery. J. Recept. Ligand Channel Res. 7, 81–92 (2014)
Machado, K.S., Schroeder, E.K., Ruiz, D.D., Cohen, E.M.L., Norberto de Souza, O.: FReDoWS: a method to automate molecular docking simulations with explicit receptor flexibility and snapshots selection. In: BMC Genomics, pp. 1–13 (2011)
Lipinski, C.A.: Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov. Today Technol. 1, 337–341 (2004)
Veber, D.F., Johnson, S.R., Cheng, H., Smith, B.R., Ward, K.W., Kopple, K.D.: Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Sci. 45, 2615–2623 (2002)
Daneman, R., Rescigno, M.: Review the gut immune barrier and the blood-brain barrier: are they so different? Immunity 31, 722–735 (2009)
Nasution, M.A.F., Toepak, E.P., Alkaff, A.H., Tambunan, U.S.F.: Flexible docking-based molecular dynamics simulation of natural product compounds and Ebola virus Nucleocapsid (EBOV NP): a computational approach to discover new drug for combating Ebola. BMC Bioinform. 19, 137–176 (2018)
Badyal, D.K., Dadhich, A.P.: Cytochrome P450 and drug interactions. Indian J. Pharmacol. 33, 248–259 (2001)
Danker, T., Möller, C.: Early identification of hERG liability in drug discovery programs by automated patch clamp. Front. Pharmacol. 5, 1–11 (2014)
Hakura, A., Shimada, H., Nakajima, M., Sui, H., Kitamoto, S., Suzuki, S.: Salmonella/human S9 mutagenicity test: a collaborative study with 58 compounds. Mutagenesis 20, 217–228 (2005)
Hansen, K., et al.: Benchmark data set for in silico prediction of Ames mutagenicity. J. Chem. Inf. Model. 49, 2077–2081 (2009)
Walum, E.: Acute oral toxicity. Environ. Health Perspect. 106, 497–503 (1998)
Li, X., et al.: In silico prediction of chemical acute oral toxicity using multi-classification methods. Chem. Inf. Model. 54, 1061–1069 (2014)
Ertl, P., Schuffenhauer, A.: Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. J. Cheminform. 11, 1–11 (2009)
Acknowledgment
This research is financially supported by the Direktorat of Research and Community Engagement of Universitas Indonesia (DRPM UI) by Hibah Publikasi Internasional Terindeks 9 (PIT9) Project. Also, I would like to thank you to Mutiara Saragih and Ahmad Husein Alkaff for proofreading this manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this paper
Cite this paper
Yulianti, Kantale, A.C.B., Tambunan, U.S.F. (2019). Discovery of Novel Alpha-Amylase Inhibitors for Type II Diabetes Mellitus Through the Fragment-Based Drug Design. In: Rojas, I., Valenzuela, O., Rojas, F., Ortuño, F. (eds) Bioinformatics and Biomedical Engineering. IWBBIO 2019. Lecture Notes in Computer Science(), vol 11465. Springer, Cham. https://doi.org/10.1007/978-3-030-17938-0_3
Download citation
DOI: https://doi.org/10.1007/978-3-030-17938-0_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-17937-3
Online ISBN: 978-3-030-17938-0
eBook Packages: Computer ScienceComputer Science (R0)